A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study

BACKGROUND: Staphylococcus aureus bacteremia is a common infection associated with significant morbidity and mortality. Telavancin is a bactericidal lipoglycopeptide active against Gram-positive pathogens, including methicillin-resistant S. aureus (MRSA). We conducted a randomized, double-blind, Pha...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Stryjewski, Martin E, Lentnek, Arnold, O’Riordan, William, Pullman, John, Tambyah, Paul Anantharajah, Miró, Jose M, Fowler Jr, Vance G, Barriere, Steven L, Kitt, Michael M, Corey, G Ralph
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2014
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4048626/
https://ncbi.nlm.nih.gov/pubmed/24884578
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2334-14-289
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados